Minneapolis, Dec. 07, 2017 — Life Epigenetics, the insurtech subsidiary of GWG Holdings, Inc. (Nasdaq:GWGH), released an infographic timeline of the impact of epigenetics on the insurance industry.The timeline shows how the Human Genome Project sparked research that led to the discovery of mortality prediction technology. Life Epigenetics holds the exclusive license for lifespan-predictive technology developed at the University of California, Los Angeles (UCLA) for the life insurance industry.The infographic is being released as a follow-up to a webinar company executives Jon Sabes and Brian Chen participated in with IRIS.xyz and ETF Trends titled “Technology that Disrupts the Life Insurance Industry.” IT is available at this link.The webinar is now available on replay to qualified financial professionals at this link: IRS.xyz/ETF Trends Webinar linkSince February, Life Epigenetics has been collecting and analyzing data from life insurance policyholders and has been discussing its work with major life insurance and reinsurance companies that have expressed interest in learning more about how the technology can add value to their businesses. In October, it has announced pilot programs with two life insurance companies to test its epigenetic-based M-Panel technology.About Life EpigeneticsLife Epigenetics is the insurtech subsidiary of GWG Holdings, Inc. (Nasdaq:GWGH) that is dedicated to creating new technology that is transformative to the way life insurance and financial services underwrite and deliver longevity-based products and services. The company’s “DNA methylation-based predictor of mortality technology,” exclusively licensed from the University of California, Los Angeles (UCLA), provides unprecedented new insight into longevity using the cutting edge science of epigenetics.For more information about Life Epigenetics, Inc., visit www.lifeegx.comAbout GWG Holdings, Inc.GWG Holdings, Inc. (Nasdaq:GWGH) is a financial services company committed to transforming the life insurance industry through disruptive and innovative products and services. The company owns Life Epigenetics and GWG Life. GWG Life is developing a suite of new longevity-based products for consumers and financial advisors under the LifeCare Xchange (LCX). The LifeCare Xchange provides consumers owning life insurance with the opportunity to exchange their life insurance into products that can be used to pay for long-term care and meet other retirement financial needs. Life Epigenetics is developing transformative M-Panel epigenetic technology to disrupt traditional life insurance underwriting practices. Since 2006, GWG Life has provided seniors over $457 million in exchange value for their life insurance and, as of September 30, 2017, owns a portfolio of over $1.62 billion in face value of policy benefits.For more information about GWG Holdings, Inc. email [email protected] or visit www.gwgh.com.Media Contact:Dan Callahan
Director of Communication
GWG Holdings, Inc.
[email protected] Attachments:A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dde54384-d281-4869-ad5c-6aacb4427777Attachments:A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/da5324b7-b118-414a-bbb6-6914715ce2c9Daniel T Callahan
Latest posts by Sarah Thompson (see all)
- "Unbanned: The Legend of AJ1" Tells True Story of the Original Air Jordan, the Shoe that Defied Everything - February 18, 2018
- New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology - February 17, 2018
- AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting - February 17, 2018